uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
Last trade$20.87
Day change-$1.01 (-4.62%)
Day range$20.56 – $22.45
Volume789,632
Market cap$1.53B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.53B
Price / earnings
—
Price / book
5.21×
Price / sales
76.1×
EV / sales
73.71×
EV / EBITDA
-8.49×
Profitability
Earnings per share
-$3.32
Return on assets
-24.76%
Return on equity
-79.04%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.17×
Current ratio
11.52×
Quick ratio
11.52×
Cash ratio
1.64×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$192.96M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for QURE, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$5.2M
$5.84M
$3.56M
$5.57M
$3.7M
$5.26M
$1.57M
$5.22M
Cost of revenue
$236K
$350K
$219K
$435K
$398K
$656K
$197K
$17.68M
Gross profit
$4.96M
$5.49M
$3.34M
$5.13M
$3.3M
$4.61M
$1.37M
-$12.46M
Selling, general and administrative
$23.92M
$17.37M
$20.07M
$21.61M
$19.44M
$13.5M
$10.91M
$11.38M
Research and development
$35.52M
$33.96M
$29.18M
$34.78M
$34.37M
$35.38M
$36.14M
$38.84M
Total operating expenses
$59.63M
$57.69M
$49.06M
$43.84M
$55.85M
$48.47M
$40.7M
$27.42M
Operating income
-$54.67M
-$52.2M
-$45.72M
-$38.71M
-$52.55M
-$43.87M
-$39.33M
-$39.88M
Interest expense
-$14.58M
-$14.37M
-$14.03M
-$14.57M
-$16.72M
-$15.59M
-$15.11M
-$14.88M
Income before taxes
-$60.54M
-$79.22M
-$53.05M
-$41M
-$71.9M
-$37.29M
-$43.14M
-$72.41M
Income taxes
$676K
$1.84M
$488K
-$3.92M
$8.63M
$425K
$496K
$856K
Net income
-$61.22M
-$81.06M
-$53.54M
-$37.09M
-$80.53M
-$37.72M
-$43.64M
-$73.26M
Net income attributable to common shareholders
-$61.22M
-$81.06M
-$53.54M
-$37.09M
-$80.53M
-$37.72M
-$43.64M
-$73.26M
EBITDA
-$49.22M
-$47.3M
-$42.76M
-$35.74M
-$48.91M
-$40.24M
-$34.8M
-$35.52M
Basic earnings per share
-$0.88
-$1.22
-$0.85
-$0.58
-$1.38
-$0.69
-$0.82
-$1.50
Diluted earnings per share
-$0.88
-$1.22
-$0.85
-$0.58
-$1.38
-$0.69
-$0.82
-$1.50
Recent news
Company coverage with links to the original publishers.
uniQure's lead gene therapy candidate, ifezuntirgene inilparvovec, for Huntington's disease has received FDA Priority Review with a May 1, 2027 decision date. The company plans to launch a confirmatory study by end of 2026 targeting 200 patients. While the regulatory milestone drove a 17.5% stock surge, mixed clinical data, widening loss estimates, and pipeline risks temper the outlook. The company maintains a strong cash position of $768.4 million expected to fund operations through 2030.
The global genomics market is projected to reach $99.26 billion by 2034, growing at 12.66% CAGR. Three stocks—Illumina, uniQure, and 10x Genomics—are highlighted as potential investments in this expanding sector, all carrying Zacks Rank #2 (Buy) ratings. Recent advances in DNA sequencing, gene therapies, and genome-editing technologies like CRISPR are driving growth in personalized medicine and synthetic biology applications.
Pomerantz LLP is investigating potential securities fraud claims against ClearPoint Neuro following a significant stock price decline. On September 29, 2026, development partner uniQure announced that their joint treatment for Huntington's disease failed to achieve statistical significance on a primary clinical measure at 48 months, causing ClearPoint's stock to plummet 23.12% to $11.77 per share.
Law firm Kirby McInerney LLP is investigating potential securities law violations by uniQure N.V. following the release of 48-month data for AMT-130 that showed significantly reduced treatment efficacy (44% disease slowing) compared to previously reported 36-month results (75% slowing). The company had submitted an FDA application based on the stronger 36-month data. uniQure's stock price declined 37.3% on the news, falling from $39.11 to $24.51 per share.
uniQure (QURE) announced mixed phase I/II data for its investigational gene therapy ifezuntirgene inilparvovec for Huntington's disease treatment. At 36 months, the therapy showed 80% slowing in cUHDRS and 67% in TFC versus external controls. However, 48-month data showed weaker results with cUHDRS at 44% slowing (not statistically significant) and TFC at 61% slowing. The stock plunged 37% following the announcement. The company has submitted a BLA to the FDA based on 36-month data, with regulatory review and durability validation as key upcoming catalysts.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.